• About us
  • Science and Pipeline
  • Investors
  • Contact us
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Jul 21, 2026 | Press Releases

Brings extensive experience in patient care, dermatologic research and commercializationKing of Prussia, Pennsylvania–(Newsfile Corp. – July 21, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

Jul 15, 2026 | Press Releases

Securing additional patent protection in the United States, Canada, and Japan for INTASYL CompoundsKing of Prussia, Pennsylvania–(Newsfile Corp. – July 15, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Jun 26, 2026 | Press Releases

Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – June 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...

Phio Pharmaceuticals Announces “How siRNA Therapy can Change the Course of Cancer Treatment” in a Fireside Chat with Force Family Office on Monday, June 29, 2026

Jun 25, 2026 | Press Releases

Live virtual fireside chat – investors, advisors, and life sciences analysts invited to attendKing of Prussia, Pennsylvania–(Newsfile Corp. – June 25, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

Jun 24, 2026 | Press Releases

Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substanceNewly manufactured supply will support upcoming clinical trial in next development phaseKing of Prussia, Pennsylvania–(Newsfile Corp. – June 24, 2026) – Phio...

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026

Jun 18, 2026 | Press Releases

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in Phio Pharmaceuticals, to attend the live, interactive presentation and one-on-one meetingsKing of Prussia, Pennsylvania–(Newsfile Corp. – June...
« Older Entries
Next Entries »

Recent Posts

  • Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
  • Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
  • Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
  • Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
  • Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Recent Comments

No comments to show.
Email Alerts

Stay up to date on news and investor alerts

Sign up now

© 2026 Phio Pharmaceuticals

  • Follow
  • Follow
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us